Annexin A5 as an Immune Checkpoint Inhibitor and Tumor-Homing Molecule for Cancer Treatment

Nature Communications- United Kingdom

doi 10.1038/s41467-020-14821-z

Full Text

Abstract

Available in

Date

Authors

Publisher

Springer Science and Business Media LLC

Related search

Immune-Checkpoint Inhibitor Treatment of Non-Small Cell Lung Cancer Patients

Jurnal Respirasi
2020English

Theranostic Tumor Homing Nanocarriers for the Treatment of Lung Cancer

Nanomedicine: Nanotechnology, Biology, and Medicine
Materials ScienceMolecular MedicineNanosciencePharmaceutical ScienceMedicineBioengineeringNanotechnologyBiomedical Engineering
2014English

Treatment Combining CD200 Immune Checkpoint Inhibitor and Tumor-Lysate Vaccination After Surgery for Pet Dogs With High-Grade Glioma

Cancers
Cancer ResearchOncology
2019English

Thyrotoxicosis and Adrenocortical Hormone Deficiency During Immune-Checkpoint Inhibitor Treatment for Malignant Melanoma

In Vivo
BiochemistryMedicineGeneticsPharmacologyMolecular Biology
2018English

TIGIT as an Emerging Immune Checkpoint

Clinical and Experimental Immunology
AllergyImmunology
2019English

Can an Immune Checkpoint Inhibitor (Sometimes) Make Things Worse?

Clinical Cancer Research
Cancer ResearchOncology
2017English

Review of Cancer Treatment With Immune Checkpoint Inhibitors

Wiener Klinische Wochenschrift
Medicine
2017English

Annexin A5 Stimulates Autophagy and Inhibits Endocytosis

Journal of Cell Science
Cell Biology
2012English

2) Lung Cancer Treatment Using Immune Checkpoint Inhibitors

Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine
Medicine
2019Italian

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy